Market cap
₹24 Cr
Revenue (TTM)
₹574 Cr
P/E Ratio
15.6
P/B Ratio
11.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹2 Cr
-
ROE
4.7 %
-
ROCE
9.6 %
-
Industry P/E
--
-
EV/EBITDA
13.2
-
Debt to Equity
0
-
Book Value
₹3.8
-
EPS
₹2.8
-
Face value
10
-
Shares outstanding
5,468,300
10 Years Aggregate
CFO
₹0.52 Cr
EBITDA
₹-0.17 Cr
Net Profit
₹-0.17 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
| -62.4 | -1.6 | -15.7 | 135.6 | -- | 60.3 | -- |
|
BSE Healthcare*
| 8.7 | 1.4 | 8.4 | 9.2 | 24.9 | 13.5 | 12.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Rubra Medicaments
| 793.4 | 168.0 | 3.1 | 11.1 | 70.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
|
43.0 | 23.5 | 573.8 | 1.5 | 0.4 | 12 | 15.6 | 11.4 |
| 3,110.0 | 37,632.5 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 35.6 | 8.3 | |
| 1,742.7 | 33,051.0 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.8 | 6.7 | |
| 1,147.3 | 4,960.9 | 6,591.2 | 145.8 | 3.4 | 7 | 43.1 | 2.9 | |
| 2,210.2 | 35,481.1 | 4,147.8 | 709.5 | 22.3 | 19.1 | 50 | 8.5 | |
| 43.6 | 19.2 | 33.3 | 0.6 | 3.6 | 12.5 | 168.3 | 4.0 | |
| 29.0 | 33.5 | 12.5 | -3.0 | -90.2 | -2.7 | -- | 0.3 | |
| 37.1 | 23.3 | 2.1 | 0.2 | -9.8 | 2 | 114.7 | 2.4 | |
| 1.8 | 7.0 | 115.9 | 0.4 | 0.6 | 8.9 | 17.8 | 1.6 | |
| 0.3 | 33.4 | 365.5 | -17.0 | -2.0 | -14.3 | -- | 0.3 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Rubra Medicaments
Rubra Medicaments Limited engages in the trade of pharmaceuticals, and other medical and surgical products in India. The company was incorporated in 1991 and is based in Mumbai, India.
-
Incorporated
1991
-
Chairman
--
-
Managing Director
Shubham Chaudhary
-
Headquarters
Nashik, Maharashtra
-
Website
Annual Reports
FAQs for Rubra Medicaments
What is the current share price of Rubra Medicaments Ltd Today?
The share price of Rubra Medicaments Ltd is ₹43.00 (BSE) as of 10-Jun-2026 09:00 IST. Rubra Medicaments Ltd has given a return of 135.62% in the last 1 years.
What is the current PB & PE ratio of Rubra Medicaments Ltd?
The P/E ratio of Rubra Medicaments Ltd is 15.58 times as on 09-Jun-2026.
The P/B ratio of Rubra Medicaments Ltd is 11.37 times as on 09-Jun-2026, a 3149 premium to its peers’ median range of 0.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
275.35
|
12.53
|
|
2024
|
178.90
|
10.14
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
6.62
|
|
2021
|
234.95
|
4.72
|
What is the 52 Week High and Low of Rubra Medicaments Ltd?
The 52-week high and low of Rubra Medicaments Ltd are Rs 144.40 and Rs 0.00 as of 10-Jun-2026.
What is the market cap of Rubra Medicaments Ltd?
Rubra Medicaments Ltd has a market capitalisation of ₹ 24 Cr as on 09-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rubra Medicaments Ltd?
Before investing in Rubra Medicaments Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.